[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:von-hippel-lindau-disease-tumor-suppressor":3},{"name":4,"total":5,"recruiting":5,"trials":6},"Von Hippel-Lindau Disease Tumor Suppressor",5,[7,15,21,27,33],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT06698003","A Study of Mogamulizumab to Prevent Adult T-cell Leukemia\u002FLymphoma in People With HTLV-1",[11],"Phase 2","RECRUITING","2026-08-26T02:18:36.226508Z","2026-05-05T02:43:27.103944Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT04924075","Belzutifan\u002FMK-6482 for the Treatment of Advanced Pheochromocytoma\u002FParaganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)",[11],"2026-08-26T02:17:01.714035Z","2026-07-05T05:32:16.796442Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":25,"content_modified":26},"NCT04074135","Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors",[11],"2026-08-26T02:18:57.189473Z","2026-05-05T02:43:27.067216Z",{"nct_id":28,"title":29,"phases":30,"status":12,"updated_at":31,"content_modified":32},"NCT03749980","MyVHL: Patient Natural History Study",[],"2026-08-26T02:18:09.641312Z","2026-05-13T02:55:06.175956Z",{"nct_id":34,"title":35,"phases":36,"status":12,"updated_at":37,"content_modified":38},"NCT00001238","Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders",[],"2026-08-26T02:16:34.792807Z","2026-07-05T18:42:10.720145Z"]